Kronos Bio Inc is a biotechnology business based in the US. Kronos Bio shares (KRON) are listed on the NASDAQ and all prices are listed in US Dollars. Kronos Bio employs 90 staff and has a market cap (total outstanding shares value) of USD$999.1 million.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Latest market close||$16.78|
|52-week range||$17.62 - $39.61|
|50-day moving average||$21.79|
|200-day moving average||$23.47|
|Wall St. target price||$42.25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.16|
Note: The dollar amounts in the table below are in Canadian dollars.
|1 week (2021-10-08)||-5.52%|
|1 month (2021-09-17)||-30.95%|
|3 months (2021-07-16)||-18.35%|
|6 months (2021-04-16)||-22.17%|
|1 year (2020-10-16)||-47.66%|
|2 years (2019-10-13)||N/A|
|3 years (2018-10-13)||N/A|
|5 years (2016-10-13)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-20.52%|
|Return on equity TTM||-50.3%|
|Market capitalisation||$999.1 million|
TTM: trailing 12 months
There are currently 4.1 million Kronos Bio shares held short by investors – that's known as Kronos Bio's "short interest". This figure is 2.2% down from 4.2 million last month.
There are a few different ways that this level of interest in shorting Kronos Bio shares can be evaluated.
Kronos Bio's "short interest ratio" (SIR) is the quantity of Kronos Bio shares currently shorted divided by the average quantity of Kronos Bio shares traded daily (recently around 212252.43775934). Kronos Bio's SIR currently stands at 19.28. In other words for every 100,000 Kronos Bio shares traded daily on the market, roughly 19280 shares are currently held short.
However Kronos Bio's short interest can also be evaluated against the total number of Kronos Bio shares, or, against the total number of tradable Kronos Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kronos Bio's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Kronos Bio shares in existence, roughly 70 shares are currently held short) or 0.0932% of the tradable shares (for every 100,000 tradable Kronos Bio shares, roughly 93 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Kronos Bio.
We're not expecting Kronos Bio to pay a dividend over the next 12 months.
Kronos Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Stock trading doesn’t have to be expensive. Using Finder’s proprietary algorithm, we’ve identified the best cheap Canadian and US stocks to buy now.Read more…
Cue Health—developer of a COVID-19 self-testing kit with conditional approval in the US, Canada, European Union and India—has gone public. Here’s how to buy in.Read more…
Steps to owning and managing ARBK stock, with 24-hour and historical pricing before you buy.Read more…
Steps to owning and managing ITUB, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing BSX stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing WM stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing MIN stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing LUC stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing GSV stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing FCU stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing AII stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing USA stock, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.